Three months ago, Fractyl Health's management sounded like a team on the verge of answering what it called the most important question in obesity. Since then, the stock has lost almost 88% of its value, sliding from a post-earnings high of $9.72 to about $0.93. The S&P 500 fell roughly 5% over the same stretch. When Fractyl reports third-quarter results after the close on November 12, the headline loss will matter less than whether management can explain what remains of the Revita thesis and how it plans to pay for it.

The Street is looking for a loss of $1.59 per share, sharply worse than the $0.12 loss last quarter and the $0.35 loss a year ago. That implies a year-over-year deterioration of more than 350%. Consensus also lists quarterly revenue of $71.4 million. That figure is hard to square with a clinical-stage company that has no commercial product, so investors should treat it cautiously. Management has not issued formal financial guidance, which leaves the balance sheet and the clinical calendar as the real yardsticks.

The prior call was built on a run of progress. One-year randomized data showed patients kept about 80% of their GLP-1 weight loss with Revita, versus 46% on sham. Open-label REVEAL-1 results of roughly 78% backed that up. Management lifted its powering assumption on both co-primary endpoints to above 95% and described a favorable de novo regulatory route. It also trimmed R&D spending for three straight quarters, to $13.8 million, while adjusted EBITDA losses narrowed to $16.3 million. The second program, the Rejuva gene therapy, cleared regulatory hurdles in the Netherlands and Australia. The calendar called for six-month pivotal top-line data early in the fourth quarter, a de novo submission late in the quarter, and 12-month pivotal data in the first quarter of 2027.

That calendar is now the crux. A collapse of this size, in the window when the pivotal readout was expected, tells you the market has sharply repriced the odds of success, whatever the precise cause. To support the earlier story, the report would need to show three things: the pivotal program still points toward a de novo filing on schedule, the co-primary endpoints remain intact, and the FDA's moderate-risk classification is still plausible after the full safety review. Any delay to the submission, a reworked endpoint strategy, or a retreat from the de novo framing would confirm the market's skepticism.

Cash is the second test, and it may prove the more pressing one. The balance fell from $81.5 million to $63.2 million to $47.1 million over three quarters. Management repeatedly said the runway extends into early 2027 and that it would not tap its at-the-market facility before pivotal data. Burn of around $16 million a quarter would leave a thin cushion at the end of September. Raising money below a dollar a share would be painfully dilutive. Look for updated runway language, any new cost cuts, and whether Rejuva spending is being scaled back to protect Revita.

Sentiment has shifted in an unusual way. The prior quarter's reading was deeply bearish. Today's is only mildly negative, suggesting many of the pessimists may have already sold. The stock sits far below its $7.40 200-day average and only modestly above its post-report low of $0.82, so expectations are low. Still, a lower bar does not fix a funding gap. The question this report must answer is whether Fractyl still has a credible, funded path to a Revita filing, or whether the confident narrative of last quarter now hinges on raising capital at a steep cost to shareholders.